Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL<sup>pro</sup> Inhibitors
The 3C-like protease (3CL<sup>pro</sup>) of SARS-CoV-2 is considered an excellent target for COVID-19 antiviral drug development because it is essential for viral replication and has a cleavage specificity distinct from human proteases. However, drug development for 3CL<sup>pro</sup> has been hinder...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2021-01-01
|
| シリーズ: | Viruses |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/1999-4915/13/2/173 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|